Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.

Abstract

PURPOSE:

Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into extravasation with new types of anthracyclines, the anthracenediones, or the liposomal pegylated anthracycline formulations. We therefore tested the antidotal efficacy of dexrazoxane against extravasation of amrubicin, mitoxantrone, and liposomal pegylated doxorubicin in mice.

METHODS:

A total of 80 female B6D2F1 mice were tested in an established mouse extravasation model. The mice had experimental extravasations of amrubicin, mitoxtanrone, and Caelyx and were immediately hereafter treated with systemic dexrazoxane or saline.

RESULTS AND CONCLUSION:

Systemic treatment with dexrazoxane resulted in significant protection against extravasation injuries from all three drugs. Moreover, the vesicant potential of the three test drugs was weaker than seen in previous experiments with the classic anthracyclines.

• Authors: Seppo W Langer, Annemette V Thougaard, Maxwell Sehested, Peter Buhl Jensen
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 69 Issue 2 Pg. 573-6 (Feb 2012) ISSN: 1432-0843 [Electronic] Germany
• PMID: 22143379 (Publication Type: Journal Article)

Chemical References

• Anthracyclines
• Antineoplastic Agents
• Razoxane
• Doxorubicin
• amrubicin
• Mitoxantrone

Topics

• Animals
• Anthracyclines (toxicity)
• Antineoplastic Agents (therapeutic use)
• Disease Models, Animal
• Doxorubicin (toxicity)
• Extravasation of Diagnostic and Therapeutic Materials (etiology, prevention & control)
• Female
• Humans
• Mice
• Mitoxantrone (toxicity)
• Razoxane (therapeutic use)
• Treatment Outcome